Are You a Health Care Professional?

This website is intended to provide information about the ongoing PACIFICA clinical trial in myelofibrosis.

The PACIFICA clinical trial is a randomized, controlled phase 3 study of pacritinib versus Physician’s Choice1 in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet counts <50,000/μL).

1Physician’s Choice is limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib.

Contact Us

© Copyright 2021 CTI BioPharma Corp.

cti-biopharma